CA2301860C - Chemical and pharmacological standardization of herbal extracts - Google Patents
Chemical and pharmacological standardization of herbal extracts Download PDFInfo
- Publication number
- CA2301860C CA2301860C CA002301860A CA2301860A CA2301860C CA 2301860 C CA2301860 C CA 2301860C CA 002301860 A CA002301860 A CA 002301860A CA 2301860 A CA2301860 A CA 2301860A CA 2301860 C CA2301860 C CA 2301860C
- Authority
- CA
- Canada
- Prior art keywords
- extract
- test
- pharmacological
- chemical
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 title claims abstract description 101
- 230000000144 pharmacologic effect Effects 0.000 title claims abstract description 61
- 239000012676 herbal extract Substances 0.000 title abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 61
- 238000012360 testing method Methods 0.000 claims description 81
- 239000000284 extract Substances 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 56
- 230000000694 effects Effects 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 38
- 238000000605 extraction Methods 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 13
- 239000000419 plant extract Substances 0.000 claims description 13
- 230000004071 biological effect Effects 0.000 claims description 3
- 241000700159 Rattus Species 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 35
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 35
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 35
- 239000000047 product Substances 0.000 description 35
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 35
- 229960002646 scopolamine Drugs 0.000 description 35
- 238000002835 absorbance Methods 0.000 description 25
- 239000002904 solvent Substances 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 22
- 241000196324 Embryophyta Species 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 21
- 230000013016 learning Effects 0.000 description 21
- 229960001231 choline Drugs 0.000 description 19
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 19
- 229930182494 ginsenoside Natural products 0.000 description 19
- 230000015654 memory Effects 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 108010025020 Nerve Growth Factor Proteins 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 238000001819 mass spectrum Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 102000010909 Monoamine Oxidase Human genes 0.000 description 15
- 108010062431 Monoamine oxidase Proteins 0.000 description 15
- 102000015336 Nerve Growth Factor Human genes 0.000 description 15
- 229940053128 nerve growth factor Drugs 0.000 description 15
- 230000014511 neuron projection development Effects 0.000 description 15
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 240000005373 Panax quinquefolius Species 0.000 description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000005445 isotope effect Effects 0.000 description 11
- 150000002605 large molecules Chemical class 0.000 description 11
- 229920002521 macromolecule Polymers 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000003568 synaptosome Anatomy 0.000 description 10
- 208000000044 Amnesia Diseases 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 210000002241 neurite Anatomy 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 229940089161 ginsenoside Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 208000026139 Memory disease Diseases 0.000 description 7
- 230000001713 cholinergic effect Effects 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 208000031091 Amnestic disease Diseases 0.000 description 6
- 230000006986 amnesia Effects 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 5
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 0 C[C@@]1C[C@@](CCC*)CC1 Chemical compound C[C@@]1C[C@@](CCC*)CC1 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004720 cerebrum Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 210000004129 prosencephalon Anatomy 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000012347 Morris Water Maze Methods 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 241000208343 Panax Species 0.000 description 3
- 229930182936 Quinquenoside Natural products 0.000 description 3
- JXRIVFVBUUJAGK-RQYLRFHSSA-N Quinquenoside R1 Natural products O=C(OC[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O[C@H]2O[C@H]2C(C)(C)[C@H]3[C@](C)([C@@H]4[C@@](C)([C@]5(C)[C@]([C@](O[C@@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](CO[C@@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O7)O6)(CC/C=C(\C)/C)C)([C@@H](O)C4)CCC5)CC3)CC2)O1)C JXRIVFVBUUJAGK-RQYLRFHSSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 235000020940 control diet Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000023060 memory loss Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- SNHCPECPLQRJNL-UHFFFAOYSA-N quinquenoside r1 Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(COC(C)=O)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O SNHCPECPLQRJNL-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000006886 spatial memory Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000001755 vocal effect Effects 0.000 description 3
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007705 chemical test Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000006049 herbal material Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 101150054987 ChAT gene Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- BXLYSRPHVMCOPS-ACZMJKKPSA-N Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO BXLYSRPHVMCOPS-ACZMJKKPSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- HEAFLBOWLRRIHV-UHFFFAOYSA-N [Na].[P] Chemical compound [Na].[P] HEAFLBOWLRRIHV-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125682 antidementia agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- FVJPPEWHZCSTAC-UHFFFAOYSA-N meta-O-Dealkylated flecainide Chemical compound OC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 FVJPPEWHZCSTAC-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000281 neuronotrophic effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002248 primary sensory neuron Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010050991 protein kinase C zeta Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XJKFZICVAPPHCK-NZPQQUJLSA-N ω cgtx Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H]1N(C[C@H](O)C1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(C[C@H](O)C1)C(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]1N(C[C@H](O)C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS)[C@@H](C)O)C1=CC=C(O)C=C1 XJKFZICVAPPHCK-NZPQQUJLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5609297P | 1997-08-28 | 1997-08-28 | |
| US60/056,092 | 1997-08-28 | ||
| PCT/US1998/017344 WO1999009837A1 (en) | 1997-08-28 | 1998-08-28 | Chemical and pharmacological standardization of herbal extracts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2301860A1 CA2301860A1 (en) | 1999-03-04 |
| CA2301860C true CA2301860C (en) | 2009-05-26 |
Family
ID=22002097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002301860A Expired - Lifetime CA2301860C (en) | 1997-08-28 | 1998-08-28 | Chemical and pharmacological standardization of herbal extracts |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6156291A (enExample) |
| EP (1) | EP1006802A4 (enExample) |
| JP (2) | JP4520033B2 (enExample) |
| KR (1) | KR20010023208A (enExample) |
| CN (1) | CN1268027A (enExample) |
| AU (1) | AU9029298A (enExample) |
| CA (1) | CA2301860C (enExample) |
| WO (1) | WO1999009837A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432454B1 (en) * | 1997-12-12 | 2002-08-13 | C. V. Technologies, Inc. | Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| ATE337788T1 (de) * | 1998-03-26 | 2006-09-15 | Phytopharm Plc | Steroidale saponine zur behandlung der alzheimerischen krankheit |
| GB9923076D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| CN1630528A (zh) * | 1999-08-30 | 2005-06-22 | 独立行政法人科学技术振兴机构 | 含药用人参的脑细胞或神经细胞保护剂 |
| JP2001139483A (ja) * | 1999-08-30 | 2001-05-22 | Japan Science & Technology Corp | 薬用人蔘からなる脳細胞または神経細胞保護剤 |
| CA2307393A1 (en) | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| US6771369B2 (en) * | 2002-03-12 | 2004-08-03 | Analytical Spectral Devices, Inc. | System and method for pharmacy validation and inspection |
| US6884627B2 (en) * | 2002-04-05 | 2005-04-26 | Advanced Gene Technology, Corp. | Method for ascertaining the quality of herbs |
| US6855343B2 (en) * | 2002-05-21 | 2005-02-15 | Advanced Gene Technology, Corp | Method to ascertain the quality of herbs |
| CA2502849A1 (en) * | 2002-10-25 | 2004-05-13 | Sloan-Kettering Institute For Cancer Research | Screening, quantitation and identification of active ingredients in natural products |
| US7491753B2 (en) | 2003-07-03 | 2009-02-17 | Mallard Creek Polymers, Inc. | Antimicrobial and antistatic polymers and methods of using such polymers on various substrates |
| MX2007000562A (es) * | 2004-07-16 | 2007-03-30 | Univ Columbia | Compuestos y su preparacion para el tratamiento de la enfermedad de alzheimer al inhibir la produccion de peptidos beta-amiloideos. |
| TWI285262B (en) * | 2005-06-20 | 2007-08-11 | Dev Center Biotechnology | Characteristic mass spectrum fingerprinting setting method and rapid identification method of Chinese herb medicine and prescription |
| US20070048249A1 (en) | 2005-08-24 | 2007-03-01 | Purdue Research Foundation | Hydrophilized bactericidal polymers |
| RU2444541C2 (ru) | 2006-08-24 | 2012-03-10 | Маллард Крик Полимерс, Инк. | Катионный латекс в качестве носителя биоактивных ингредиентов и способы его получения и использования |
| EP2135074B1 (en) * | 2007-03-30 | 2016-08-31 | Sinoveda Canada Inc | Pharmaceutical platform technology for the development of natural products |
| WO2009094177A1 (en) | 2008-01-24 | 2009-07-30 | Raptor Therapeutics Inc. | Protopanaxadiol-type ginsenoside compositions and uses thereof |
| CN102014941B (zh) * | 2008-02-29 | 2013-11-06 | 阿费克萨生命科学公司 | 人参提取物对固有及适应性免疫应答的激活 |
| US20100278944A1 (en) * | 2009-05-04 | 2010-11-04 | Naturex, S.A. | Application of american ginseng to enhance neurocognitive function |
| US9956241B2 (en) | 2009-05-04 | 2018-05-01 | Naturex, S.A. | Application of American Ginseng to enhance neurocognitive function |
| KR20110007473A (ko) * | 2009-07-16 | 2011-01-24 | 씨제이제일제당 (주) | 진세노사이드 강화 분획물을 포함하는 혈압 강하용 조성물 |
| JP5563285B2 (ja) * | 2009-12-14 | 2014-07-30 | ライオン株式会社 | 飲食品、医薬品、又は医薬部外品、並びに、プロトパナキサトリオールの安定化方法、及びプロトパナキサジオールの安定化方法 |
| US20110177179A1 (en) * | 2010-01-18 | 2011-07-21 | Sinoveda Canada, Inc. | Preparation of botanical extracts containing absorbable components using pharmaceutical platform technology |
| CN105188724A (zh) * | 2013-03-14 | 2015-12-23 | 张宗超 | 用于测定草药的活性成分及其产生的来源和催化途径的方法 |
| US20150044306A1 (en) | 2013-08-12 | 2015-02-12 | Melvin Mitchell | Process for fractionation and extraction of herbal plant material to isolate extractives for pharmaceuticals and nutraceuticals |
| US20160085941A1 (en) * | 2015-03-13 | 2016-03-24 | Jianyi Zhang | Method of Discovery of Effective Components in Herbals Based on Evidences by Reversed-directed Analysis |
| EP3629731A1 (en) | 2017-05-27 | 2020-04-08 | Poly Group LLC | Dispersible antimicrobial complex and coatings therefrom |
| HUE068413T2 (hu) | 2017-06-16 | 2024-12-28 | Poly Group LLC | Polimer, antimikrobiális felületaktív anyag |
| BE1027552B1 (fr) | 2019-09-03 | 2021-03-30 | Botalys Sa | Composition du ginseng et son utilisation comme medicament pour le traitement ou la prevention du stress |
| WO2021043927A1 (en) | 2019-09-03 | 2021-03-11 | Botalys Sa | Ginseng composition and use thereof as a medicament |
| BE1027772B1 (fr) | 2019-11-21 | 2021-06-21 | Botalys Sa | Composition de ginseng pour ameliorer l'etat de la peau et son utilisation pour le traitement d'une maladie dermatologique |
| WO2021043389A1 (en) | 2019-09-03 | 2021-03-11 | Botalys Sa | Ginseng composition and use thereof as a medicament for treatment or prevention of an impaired cognition |
| US10881983B2 (en) * | 2019-09-18 | 2021-01-05 | The Winning Combination | Method for extraction of ethyl maltol from passion flower |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0753397A (ja) * | 1993-08-19 | 1995-02-28 | Inahata Koryo Kk | 変異原性抑制剤 |
| JPH07126618A (ja) * | 1993-11-04 | 1995-05-16 | Jumoku Chushutsu Seibun Riyou Gijutsu Kenkyu Kumiai | 抗酸化剤 |
| US5565200A (en) * | 1995-04-14 | 1996-10-15 | University Of Southern California | Pharmaceutical preparations derived from korean mistletoe |
| US6039950A (en) * | 1995-04-14 | 2000-03-21 | University Of Southern California | Pharmaceutical grade saw palmetto |
| US5547674A (en) * | 1995-04-14 | 1996-08-20 | University Of Southern California | Pharmaceutical preparations derived from European mistletoe |
| JPH11503453A (ja) * | 1995-04-14 | 1999-03-26 | ユニバーシティー オブ サザン カリフォルニア | ヤドリギ抽出物および方法 |
-
1998
- 1998-08-28 US US09/143,361 patent/US6156291A/en not_active Expired - Lifetime
- 1998-08-28 JP JP2000507241A patent/JP4520033B2/ja not_active Expired - Fee Related
- 1998-08-28 AU AU90292/98A patent/AU9029298A/en not_active Abandoned
- 1998-08-28 CA CA002301860A patent/CA2301860C/en not_active Expired - Lifetime
- 1998-08-28 EP EP98942181A patent/EP1006802A4/en not_active Ceased
- 1998-08-28 CN CN98808588A patent/CN1268027A/zh active Pending
- 1998-08-28 KR KR1020007001837A patent/KR20010023208A/ko not_active Ceased
- 1998-08-28 WO PCT/US1998/017344 patent/WO1999009837A1/en not_active Ceased
-
2009
- 2009-09-18 JP JP2009218142A patent/JP5491114B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001513533A (ja) | 2001-09-04 |
| EP1006802A1 (en) | 2000-06-14 |
| JP2009292844A (ja) | 2009-12-17 |
| WO1999009837A1 (en) | 1999-03-04 |
| JP5491114B2 (ja) | 2014-05-14 |
| EP1006802A4 (en) | 2004-01-14 |
| CN1268027A (zh) | 2000-09-27 |
| JP4520033B2 (ja) | 2010-08-04 |
| US6156291A (en) | 2000-12-05 |
| KR20010023208A (ko) | 2001-03-26 |
| CA2301860A1 (en) | 1999-03-04 |
| AU9029298A (en) | 1999-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6156291A (en) | Chemical and pharmacological standardization of herbal extracts | |
| US6083932A (en) | Pharmaceutical compositions derived from ginseng and methods of treatment using same | |
| Geula et al. | Loss of calbindin‐D28k from aging human cholinergic basal forebrain: relation to neuronal loss | |
| Schellenberg et al. | The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism | |
| EP2185167B1 (en) | System and method for assessing traditional medicines | |
| CN109596751A (zh) | 一种清热养阴活血祛瘀的脉络宁口服液成分检测方法 | |
| EP1151292B1 (en) | Process for quality control and standardisation of medicinal plant products | |
| CN111487347B (zh) | 枳术颗粒指纹图谱的检测方法 | |
| Xu et al. | Quality evaluation of traditional chinese medicine prescription in naolingsu capsule based on combinative method of fingerprint, quantitative determination, and chemometrics | |
| Chan et al. | Quercetin Potentiates the NGF‐Induced Effects in Cultured PC 12 Cells: Identification by HerboChips Showing a Binding with NGF | |
| CN111948330B (zh) | 仁术健胃颗粒指纹图谱的检测方法 | |
| Miao et al. | Meeting the challenge 2: identification of potential chemical probes for Parkinson’s disease from Ligusticum chuanxiong Hort using cytological profiling | |
| CN110297060A (zh) | 一种山苦荬药材指纹图谱检测方法及其指纹图谱 | |
| CN113009040B (zh) | 一种强力枇杷露指纹图谱的检测方法及其指纹图谱 | |
| Mădălina-Georgiana et al. | Assessing β-sitosterol levels in dietary supplements for benign prostatic hyperplasia: implications for therapeutic efficacy | |
| Liao et al. | Metabolite profile changes in different regions of rat brain affected by Ephedra sinica | |
| HK1027946A (en) | Chemical and pharmacological standardization of herbal extracts | |
| Shasha et al. | Evaluation of Baishao (Paeoniae Radix Alba) and Chishao (Paeoniae Radix Rubra) from different origins based on characteristic spectra of amino acids | |
| CN111474276B (zh) | 一种健阳片制剂的质量控制方法 | |
| Dubey et al. | Pharmacognostical and Pharmaceutical Analysis of Dviruttara Hingvadi Churna–An Ayurvedic Herbal Formulation for Purishaja Udavarta by Charaka Samhita | |
| Li et al. | Identifying the quality markers accelerating wound repair in Lamiophlomis rotata by mass spectrometry imaging | |
| Chi et al. | Integrated evaluation of HPLC fingerprints for the quality control of Ginseng Yang Rong Wan by multi-wavelength fusion fingerprint method | |
| Zhang et al. | Anticonvulsant and sedative effect of Fufang Changniu pills and probable mechanism of action in mice | |
| CN120577425A (zh) | 双金胃肠胶囊特征图谱的构建方法 | |
| CN118892478A (zh) | 苍术素在制备用于预防和/或治疗记忆障碍症的药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180828 |